Cellular inflammation in pulmonary hypertension: Detailed analysis of lung and right ventricular tissue,circulating immune cells and effects of a dual endothelin receptor antagonist
Restricted accessResearch articleFirst published online January 24, 2020
Cellular inflammation in pulmonary hypertension: Detailed analysis of lung and right ventricular tissue,circulating immune cells and effects of a dual endothelin receptor antagonist
Growing evidence suggests that inflammation is crucially involved in the pathogenesis of pulmonary hypertension (PH) and consecutive right heart failure. The present study analyzed the inflammatory response in lung and right ventricle in a rat model of PH and evaluated the effects of the dual endothelin receptor antagonist (ERA) Macitentan. PH was induced by monocrotalin (60 mg/kg body weight s.c.) in Sprague-Dawley rats (PH, n = 10) and compared to healthy controls (CON, n = 10) as well as monocrotalin-induced, macitentan-treated rats (THER, n = 10). Detection of Dendritic cells (DCs), regulatory T cells (Tregs) and others as well as RT-PCR based inflammatory gene expression analysis were performed. Circulating DCs and Tregs were quantified by flow cytometry in the rat model and in PH patients (n = 70) compared to controls (n = 52). Inflammatory cells were increased in lung and right ventricular tissue, whereas DCs and Tregs were decreased in blood. Expression of 17 genes in the lung and 20 genes in the right ventricle were relevantly (>2.0 fold) regulated in the PH group. These effects were, at least in part, attenuated in response to Macitentan treatment. In humans as well as rats, immune cells showed significant correlations to clinical, echocardiographic, and haemodynamic parameters. PH is accompanied by a distinct inflammatory response in lung and right but not left ventricular tissue attenuated by Macitentan. Correlations of circulating DCs as well as tissue resident immune cells with parameters reflecting right ventricular function raise the idea of both, promising biomarkers and novel treatment strategies.
GalieN, HumbertM, VachieryJL, GibbsS, LangI, TorbickiA, et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). European Heart Journal. 2016;37(1):67–119.
2.
BenzaRL, MillerDP, BarstRJ, BadeschDB, FrostAE, McGoonMD. An evaluation of long-term survival from time of diagnosis in pulmonary arterial hypertension from the REVEAL Registry. Chest. 2012;142(2):448–56.
3.
Vonk-NoordegraafA, HaddadF, ChinKM, ForfiaPR, KawutSM, LumensJ, et al. Right heart adaptation to pulmonary arterial hypertension: Physiology and pathobiology. Journal of the American College of Cardiology. 2013;62(25 Suppl):D22–33.
4.
McLaughlinVV, ArcherSL, BadeschDB, BarstRJ, FarberHW, LindnerJR, et al. ACCF/AHA 2009 expert consensus document on pulmonary hypertension: A report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association: Developed in collaboration with the American College of Chest Physicians, American Thoracic Society, Inc., and the Pulmonary Hypertension Association. Circulation. 2009;119(16):2250–94.
5.
HaddadF, DoyleR, MurphyDJ, HuntSA. Right ventricular function in cardiovascular disease, part II: Pathophysiology, clinical importance, and management of right ventricular failure. Circulation. 2008;117(13):1717–31.
6.
BogaardHJ, AbeK, Vonk NoordegraafA, VoelkelNF. The right ventricle under pressure: Cellular and molecular mechanisms of right-heart failure in pulmonary hypertension. Chest. 2009;135(3):794–804.
7.
SamsonN, PaulinR. Epigenetics, inflammation and metabolism in right heart failure associated with pulmonary hypertension. Pulmonary circulation. 2017;7(3):572–87.
8.
ZlupkoM, HarhayMO, GallopR, ShinJ, Archer-ChickoC, PatelR, et al. Evaluation of disease-specific health-related quality of life in patients with pulmonary arterial hypertension. Respir Med. 2008;102(10):1431–8.
9.
BatalO, KhatibOF, BairN, AboussouanLS, MinaiOA. Sleep quality, depression, and quality of life in patients with pulmonary hypertension. Lung. 2011;189(2):141–9.
10.
StacherE, GrahamBB, HuntJM, GandjevaA, GroshongSD, McLaughlinVV, et al. Modern age pathology of pulmonary arterial hypertension. Am J Respir Crit Care Med. 2012;186(3):261–72.
AngeliniDJ, SuQ, Yamaji-KeganK, FanC, TengX, HassounPM, et al. Resistin-like molecule-beta in scleroderma-associated pulmonary hypertension. Am J Respir Cell Mol Biol. 2009;41(5):553–61.
13.
DorfmullerP, PerrosF, BalabanianK, HumbertM. Inflammation in pulmonary arterial hypertension. Eur Respir J. 2003;22(2):358–63.
14.
NicollsMR, Taraseviciene-StewartL, RaiPR, BadeschDB, VoelkelNF. Autoimmunity and pulmonary hypertension: A perspective. Eur Respir J. 2005;26(6):1110–8.
15.
PerrosF, DorfmullerP, MontaniD, HammadH, WaelputW, GirerdB, et al. Pulmonary lymphoid neogenesis in idiopathic pulmonary arterial hypertension. Am J Respir Crit Care Med. 2012;185(3):311–21.
16.
HumbertM, MontiG, BrenotF, SitbonO, PortierA, Grangeot-KerosL, et al. Increased interleukin-1 and interleukin-6 serum concentrations in severe primary pulmonary hypertension. Am J Respir Crit Care Med. 1995;151(5):1628–31.
17.
DolencJ, SebestjenM, VrtovecB, KozeljM, HaddadF. Pulmonary hypertension in patients with advanced heart failure is associated with increased levels of interleukin-6. Biomarkers. 2014;19(5):385–90.
18.
RohmI, AderholdN, RatkaJ, GoebelB, FranzM, PistulliR, et al. Hypobaric hypoxia in 3000 m altitude leads to a significant decrease in circulating plasmacytoid dendritic cells in humans. Clin Hemorheol Microcirc. 2016;63(3):257–65.
19.
YilmazA, FuchsT, DietelB, AltendorfR, CichaI, StumpfC, et al. Transient decrease in circulating dendritic cell precursors after acute stroke: Potential recruitment into the brain. Clin Sci (Lond). 2009;118(2):147–57.
20.
KretzschmarD, RohmI, SchallerS, BetgeS, PistulliR, AtiskovaY, et al. Decrease in circulating dendritic cell precursors in patients with peripheral artery disease. Mediators Inflamm. 2015;2015:450957.
21.
HawigerD, InabaK, DorsettY, GuoM, MahnkeK, RiveraM, et al. Dendritic cells induce peripheral T cell unresponsiveness under steady state conditions in vivo. J Exp Med. 2001;194(6):769–79.
22.
HawigerD, WanYY, EynonEE, FlavellRA. The transcription cofactor Hopx is required for regulatory T cell function in dendritic cell-mediated peripheral T cell unresponsiveness. Nat Immunol. 2010;11(10):962–8.
23.
KretschmerK, ApostolouI, HawigerD, KhazaieK, NussenzweigMC, von BoehmerH. Inducing and expanding regulatory T cell populations by foreign antigen. Nat Immunol. 2005;6(12):1219–27.
24.
MengX, YangJ, DongM, ZhangK, TuE, GaoQ, et al. Regulatory T cells in cardiovascular diseases. Nat Rev Cardiol. 2016;13(3):167–79.
25.
RohmI, AtiskovaY, DrobnikS, FritzenwangerM, KretzschmarD, PistulliR, et al. Decreased regulatory T cells in vulnerable atherosclerotic lesions: Imbalance between pro- and anti-inflammatory cells in atherosclerosis. Mediators Inflamm. 2015;2015:364710.
26.
NiessnerA, WeyandCM. Dendritic cells in atherosclerotic disease. Clin Immunol. 2010;134(1):25–32.
27.
StenmarkKR, MeyrickB, GalieN, MooiWJ, McMurtryIF. Animal models of pulmonary arterial hypertension: The hope for etiological discovery and pharmacological cure. Am J Physiol Lung Cell Mol Physiol. 2009;297(6):L1013–32.
28.
GalieN, HumbertM, VachieryJL, GibbsS, LangI, TorbickiA, et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Heart J. 2016;37(1):67–119.
29.
NguyenTD, ShinguY, SchwarzerM, SchrepperA, DoenstT. The E-wave deceleration rate E/DT outperforms the tissue Doppler-derived index E/e’ in characterizing lung remodeling in heart failure with preserved ejection fraction. PLoS One. 2013;8(12):e82077.
30.
FranzM, GrunK, BetgeS, RohmI, Ndongson-DongmoB, BauerR, et al. Lung tissue remodelling in MCT-induced pulmonary hypertension: A proposal for a novel scoring system and changes in extracellular matrix and fibrosis associated gene expression. Oncotarget. 2016.
31.
CutticaMJ, LangenickelT, NoguchiA, MachadoRF, GladwinMT, BoehmM. Perivascular T-cell infiltration leads to sustained pulmonary artery remodeling after endothelial cell damage. Am J Respir Cell Mol Biol. 2011;45(1):62–71.
32.
del RioML, BernhardtG, Rodriguez-BarbosaJI, ForsterR. Development and functional specialization of CD103+dendritic cells. Immunol Rev. 2010;234(1):268–81.
33.
SteinmanRM, IdoyagaJ. Features of the dendritic cell lineage. Immunol Rev. 2010;234(1):5–17.
KalogeropoulosAS, TsiodrasS, RigopoulosAG, SakadakisEA, TriantafyllisA, KremastinosDT, et al. Novel association patterns of cardiac remodeling markers in patients with essential hypertension and atrial fibrillation. BMC Cardiovasc Disord. 2011;11:77.
36.
TullosNA, StewartNJ, DavidovichR, ChadeAR. Chronic blockade of endothelin A and B receptors using macitentan in experimental renovascular disease. Nephrol Dial Transplant. 2015;30(4):584–93.
ZhangJ, ZhangY, LiN, LiuZ, XiongC, NiX, et al. Potential diagnostic biomarkers in serum of idiopathic pulmonary arterial hypertension. Respir Med. 2009;103(12):1801–6.
39.
SzebeniJ, BaranyiL, SavayS, BodoM, MorseDS, BastaM, et al. Liposome-induced pulmonary hypertension: Properties and mechanism of a complement-mediated pseudoallergic reaction. Am J Physiol Heart Circ Physiol. 2000;279(3):H1319–28.
40.
KonyaC, PazZ, ApostolidisSA, TsokosGC. Update on the role of Interleukin 17 in rheumatologic autoimmune diseases. Cytokine. 2015;75(2):207–15.
41.
BalanescuP, LadaruA, BalanescuE, NicolauA, BaicusC, DanGA. IL-17, IL-6 and IFN-gamma in Systemic Sclerosis Patients. Rom J Intern Med. 2015;53(1):44–9.
42.
WitteE, WitteK, WarszawskaK, SabatR, WolkK. Interleukin-22: A cytokine produced by T, NK and NKT cell subsets, with importance in the innate immune defense and tissue protection. Cytokine Growth Factor Rev. 2010;21(5):365–79.
BauerEM, ShapiroR, ZhengH, AhmadF, IshizawarD, ComhairSA, et al. High mobility group box 1 contributes to the pathogenesis of experimental pulmonary hypertension via activation of Toll-like receptor 4. Mol Med. 2013;18:1509–18.
47.
MorethK, BrodbeckR, BabelovaA, GretzN, SpiekerT, Zeng-BrouwersJ, et al. The proteoglycan biglycan regulates expression of the B cell chemoattractant CXCL13 and aggravates murine lupus nephritis. The Journal of clinical investigation. 2010;120(12):4251–72.
48.
IozzoRV, SchaeferL. Proteoglycans in health and disease: Novel regulatory signaling mechanisms evoked by the small leucine-rich proteoglycans. The FEBS journal. 2010;277(19):3864–75.
49.
FarkasD, KraskauskasD, DrakeJI, AlhussainiAA, KraskauskieneV, BogaardHJ, et al. CXCR4 inhibition ameliorates severe obliterative pulmonary hypertension and accumulation of C-kit(+) cells in rats. PloS one. 2014;9(2):e89810.
50.
DrummondS, RamachandranS, TorresE, HuangJ, HehreD, SuguiharaC, et al. CXCR4 blockade attenuates hyperoxia-induced lung injury in neonatal rats. Neonatology. 2015;107(4):304–11.
